Per Wiik Johansen
Papers
1
Total Citations
22
H-Index
1
About
Per Wiik Johansen is a clinical pharmacologist whose research centers on pharmacogenomics, cardiovascular pharmacotherapy, and the genetic determinants of drug response. His most influential work explores how genetic variations in CYP2C9 and VKORC1 influence warfarin dosing and anticoagulation control in patients with myocardial infarction. In his 2008 study, cited 22 times, Johansen demonstrated that individual warfarin dose requirements are significantly shaped by these genetic polymorphisms, providing critical insights for personalized anticoagulation therapy. This contribution has helped bridge the gap between genomic science and clinical practice, particularly in managing high-risk cardiovascular patients. Beyond this landmark paper, Johansen’s broader research portfolio advances the understanding of how genetic factors affect drug metabolism and therapeutic outcomes, with implications for safer, more effective prescribing. His work has been instrumental in highlighting the clinical utility of pharmacogenetic testing, especially for drugs with narrow therapeutic windows like warfarin. By integrating genetic data into dosing algorithms, Johansen’s research continues to inform precision medicine approaches that reduce adverse events and improve patient care in cardiovascular disease management.
Research Focus
Key Achievements
Top Papers
- 1